The Historical Under-pricing of Initial Public Offerings (IPOs)

Published 27-JUL-2017 12:46 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Initial Public Offerings (IPOs) are the mechanism by which private companies first make their shares available for purchase by the general public. This is known as the “primary market”, and involves the company either selling their shares directly to investors in a “primary issue”, or by first passing the risk of distributing the shares to a financial organisation in a process known as “underwriting”. Once the shares have been issued, they will typically trade on a “secondary market” such as a stock exchange – which in Australia usually means the ASX.

Investing in IPOs can be incredibly lucrative, with even the largest and most valuable companies in the world at some point having a public issue, often at incredibly attractive prices. Indeed, if you had invested even a few thousand dollars into the IPOs of companies like Apple or Google, your positions would be worth millions of dollars today.

However it should be noted that IPOs are very high risk and this article is not intended as investment advice. Please seek professional financial advice before making any investment decision in any IPO or the companies mentioned in this article.

Less glamourous IPOs may also do exceptionally well, with JB Hi-Fi (which listed on the ASX in 2003) now trading at more than 1,200% of its IPO price; which is an exceptional result that doesn’t even take into account the company’s generous dividends.

Whilst it is true that not every IPO will outperform, historical analysis shows that IPOs will typically rise on their first day of listing. This is often called to as “under-pricing” and it refers to the first day return that an investor would achieve if they purchased the IPO.

IPO statistics

A study of more than 8,000 IPOs from US equity markets between 1980 and 2015 showed that the average first day return of an IPO was 18 percent. The data was compiled by “Mr. IPO” Jay R. Ritter, Cordell Professor of Finance at the University of Florida. His findings support the theory that the majority of IPOs are under-priced, which may be due to any number of reasons.

Under-pricing may occur as a deliberate attempt to generate additional interest in a stock when it first becomes publically traded. However, this is a bit of a balancing act, because if the IPO is too heavily under-priced, the company issuing the shares may be leaving additional capital on the table that they otherwise may have raised to fund their business.

However, some experts believe that under-pricing is less the result of deliberate underquoting by issuers or underwriters, and more likely the result of over-exuberance from investors. This is supported by evidence showing that IPO performance starts to decline to more normal market levels the longer the position is held.

The under-pricing of IPOs has led to a strategy known as “stagging out”. “Stagging out”, “a stag profit”, or “flipping” refers to buying into an IPO with the intention of selling for (hopefully) a profit at the start of trading on the secondary market/stock exchange. The data compiled by Professor Ritter shows that this has been a lucrative strategy in US equity markets since the late 1980s.

The Australian IPO market has also shown evidence of under-pricing; with an average first day return of 16.6% for an Australian IPO in 2016, as quoted in the On Market 2016 IPO Report.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X